How have the shares performed?
Allakos Inc. (ALLK) saw an uptrend of 2.30% in the recent trading with $101.44 being its most recent. The current price level -35.79% lower than the highest price of $157.98 marked by the stock while trading over the past 52-weeks, whereas it is 62.72% higher than the lowest price of $62.34 the company dropped to over past 52-weeks. The latest news story on ALLK appeared in GlobeNewswire under the title “New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms” on May-24-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -11.11% below one month high and is +13.00% above of the lowest during that time. Looking into the simple moving average, Allakos Inc. (ALLK)’s stock stands at a SMA-50 of $106.07 while that of 5-day is reading $100.35.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and ALLK’s SMA-200 as of now is $107.54.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 10 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.10 for the stock.
Allakos Inc. Earnings – What Happened With ALLK
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Allakos Inc. (ALLK) last released financial results for the quarter that ended 3/30/2021, posting a surprise factor of -18.20% for net revenue.
ALLK – Allakos Inc. Stock Earnings Estimates
The perspective of Allakos Inc. (NASDAQ:ALLK)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.88 for stock’s EPS in the current quarter. 9 analysts covering the stock at Wall Street were agreed upon that EPS consensus. Company’s EPS for the last quarter was -1.04.
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 53.19 million. ALLK does have institutional investors; and they hold 99.20% of the stock.
Allakos Inc. – Insider Activity and Holdings
Moreover, the latest SEC filings also revealed that stock came across 23 new insider purchases involving 412,367 shares. On the other hand, ALLK declared 708,551 shares have been sold in 79 insider transactions over the past three months.
As on Dec 30, 2020, Capital World Investors was the top most holder in Allakos Inc. (NASDAQ:ALLK) with an ownership of 6.43 million shares of the company or 12.02% of the stake worth $900.43 million. The filing also reveals Capital Research Global Investors as the second largest holder in the company with a control over 11.85% of the outstanding shares. Its stake is worth $887.46 million for having 6.34 million shares in hand.
Blackrock Inc. also came holding a key position in the company during the recent quarter and it now holds 6.60% of the outstanding shares. With this there are now 237 institutions which have possession in ALLK’s shares.
Currently, the stock has been recommended as Moderate Buy by 10 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.10 for the stock.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Allakos Inc. was 29.81 while posting a debt to equity ratio of 0.00. The count was 6.54 for long-term debt to equity ratio.
Allakos Inc.’s return on equity, or ROE, is -34.00%, compared to the industry average of -40.83% for Healthcare – Biotechnology. Although this indicates that ALLK uses its equity well, the metric will vary significantly depending on the industry.